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Abstract
Malaria is undoubtedly the world’s most devastating parasitic disease,
affecting 300 to 500 million people every year. Some cases of Plasmo-
dium falciparum infection progress to the deadly forms of the disease
responsible for 1 to 3 million deaths annually. P. falciparum-infected
erythrocytes adhere to host receptors in the deep microvasculature of
several organs. The cytoadhesion of infected erythrocytes to placental
syncytiotrophoblast receptors leads to pregnancy-associated malaria
(PAM). This specific maternal-fetal syndrome causes maternal ane-
mia, low birth weight and the death of 62,000 to 363,000 infants per
year in sub-Saharan Africa, and thus has a poor outcome for both
mother and fetus. However, PAM and non-PAM parasites have been
shown to differ antigenically and genetically. After multiple pregnan-
cies, women from different geographical areas develop adhesion-
blocking antibodies that protect against placental parasitemia and
clinical symptoms of PAM. The recent description of a new parasite
ligand encoded by the var2CSA gene as the only gene up-regulated in
PAM parasites renders the development of an anti-PAM vaccine more
feasible. The search for a vaccine to prevent P. falciparum sequestra-
tion in the placenta by eliciting adhesion-blocking antibodies and a
cellular immune response, and the development of new methods for
evaluating such antibodies should be key priorities in mother-child
health programs in areas of endemic malaria. This review summarizes
the main molecular, immunological and physiopathological aspects
of PAM, including findings related to new targets in the P. falciparum
var gene family. Finally, we focus on a new methodology for mimick-
ing cytoadhesion under blood flow conditions in human placental
tissue.
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Introduction
Globally, malaria is the most widespread
human parasitic disease, affecting 300 to
500 million people per year. Four species of
Plasmodium can infect humans: P. falcipa-
rum, P. vivax, P. malariae, and P. ovale. No
complications are observed in most malaria
cases, but some P. falciparum infections
develop into severe forms of the disease,
such as cerebral malaria and pregnancy-as-
sociated malaria (PAM), which cause more
than two million deaths annually. It is esti-
mated that 2.4 billion people, almost half the
world’s population, are at risk of contracting
malaria. In subtropical regions, and sub-
Saharan African countries in particular, this
disease limits economic development. The
control of this disease has been hampered by
the alarming spread of drug-resistant para-
sites, insecticide-resistant mosquitoes, and
the lack of an effective vaccine.
The situation has been aggravated by the
deterioration of socioeconomic conditions
in rural areas and disordered human migra-
tion in countries in which malaria is en-
demic. These factors have contributed to the
re-emergence of malaria. As a result, much
of the current research into malaria contin-
ues to focus on attempts to develop a vaccine
capable of controlling parasite transmission.
Some promising results have been obtained,
but it seems unlikely that a vaccine confer-
ring significant levels of immune protection,
particularly against severe infection, will be
developed in the near future.
Severe malaria and Plasmodium
falciparum cytoadhesion
Severe malaria is a multifactorial phe-
nomenon involving the sequestration of P.
falciparum-infected erythrocytes (IE) in deep
vascular beds and the production of inflam-
matory cytokines, such as TNF-α and IFN-γ
(1). IE adhere directly to various host endo-
thelial receptors, including CD36, intracel-
lular adhesion molecule-1 (ICAM-1), vas-
cular cellular adhesion molecule-1 (VCAM-
1), E-selectin, P-selectin, hyaluronic acid
(HA), and chondroitin sulfate-A (CSA), or
to other IE. They may also form rosettes by
adhering to non-infected erythrocytes (Fig-
ure 1B) (2). It has been suggested that adhe-
sion to host receptors expressed on the sur-
face of endothelial cells enables IE to avoid
spleen-mediated filtration and host immune
attack, potentially implicating cytoadhesion
in parasite survival (3). In addition to direct
parasite adhesion to host receptors, platelets
can act as a bridge between IE and endothe-
lial cells, providing additional CD36 recep-
tors for cytoadhesion (Figure 1A).
Following infection, P. falciparum pro-
teins are exported to the erythrocyte surface,
altering host cell conformation and generat-
ing electron-dense structures. These struc-
tures are known as knobs (Figure 1), and
correspond to IE-binding sites adhering to
the host endothelium. Knobs are composed
of several polypeptides, including P. falci-
parum erythrocyte membrane protein 1
(PfEMP-1; Figure 2A). PfEMP-1 is a vari-
able protein 200 to 350 kDa in size, encoded
by the members of the var multigene family,
which are present as about 60 distinct copies
per haploid parasite genome. These proteins
mediate both antigenic variation and cyto-
adhesion (2,4), and therefore play an impor-
tant role in parasite virulence. It has been
suggested that var gene diversity is largely
based on the clustering of these genes at the
ends of several chromosomes, creating a
“hot-spot” recombination zone facilitating
the alignment of homologous sequences lo-
cated on heterologous chromosomes. De-
spite this variability, only one antigenic vari-
ant is expressed on the surface of the IE at a
given time (5). PfEMP-1 contains a trans-
membrane and an extracellular region, which
has been implicated in binding to the cytoad-
hesion-binding site and as a target for the
host immune response (Figure 2A). This
extracellular region has a succession of bind-
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Figure 1. Sequestration mechan-
isms involved in Plasmodium fal-
ciparum infections. P. falcipa-
rum-infected erythrocytes (IE)
adhere directly to different re-
ceptors on the host endothelium
via knobs (A); to other IE by
auto-agglutination (B); to non-in-
fected erythrocytes (nIE), form-
ing rosettes (C); to platelets,
which act as a bridge in IE
cytoadhesion via the CD36 re-
ceptor (D). All these phenomena
are thought to contribute to blood
flow occlusion (E) and produc-
tion of the inflammatory cyto-
kines, TNF-α and IFN-γ (F); thus
leading to the poor clinical out-
comes observed in severe ma-
laria.
Figure 2. Schematic structure of
Plasmodium falciparum erythro-
cyte membrane protein-1 (PfEPM-
1). The intracellular and the im-
munogenic extracellular regions
of a PfEMP-1 are represented.
A, One PfEMP-1 encoded by a
var gene contains several Duffy
binding-like (DBL) domains in-
tercalated by cysteine-rich inter-
domain region domains (CIDR),
responsible for mediating para-
site cytoadhesion to different re-
ceptors directly on the host en-
dothelium, multiadhesion, or ad-
hesion to non-infected erythro-
cytes, forming rosettes. NTS =
N-terminal segment; TM = trans-
membrane domain; ATS = acidic
teminal segment; CR1 = com-
plement receptor 1; ICAM-1 =
intracellular adhesion molecule
1; PECAM-1 = platelet endothe-
lial cell adhesion molecule; CSA
= chondroitin sulfate A. B, The
PfEMP-1 encoded by the var2CSA
gene 3D7gDNA-PFL0030cvar
contains DBL domains capable
of CSA-binding and inter-do-
main regions (ID).
1528
Braz J Med Biol Res 39(12) 2006
F.T.M. Costa et al.
ing sites arranged in tandem at the N-termi-
nal end of the molecule (Figure 2A). These
motifs are known as Duffy binding-like
(DBL) domains, as they were first identified
in P. vivax Duffy binding protein, interca-
lated by cysteine-rich interdomain region
domains (CIDR). Both CIDR and DBL re-
gions can be identified on the basis of their
amino-acid sequences (2,4).
Different PfEMP-1 molecules have bind-
ing sites for adhesion to different host recep-
tors (Figure 2A), such as CD36, ICAM-1,
VCAM-1, E-selectin, P-selectin, CSA, and
others dependent on multiple functional bind-
ing domains within PfEMP-1. For example,
adhesion to CD36, ICAM-1 and CSA is
mediated by different PfEMP-1 variants, as
var genes are expressed in a mutually exclu-
sive manner, with only one PfEMP-1 ex-
pressed on the surface of an IE at a given
time (5). Thus, placental parasites can bind
CSA, but not the CD36 receptor (6). This
dichotomous behavior may result from dif-
ferences in gene location and transcription
orientations between CSA-binding and non-
binding parasites (7-8).
General aspects of PAM
After years of exposure to the parasite,
individuals living in areas of endemic ma-
laria acquire high levels of immunity, limit-
ing parasitemia and attenuating the clinical
outcome of malaria. However, pregnant
women remain susceptible, especially in their
first pregnancy, in which case the risk of
contracting malaria is two to ten times higher
than that in non-pregnant women living in
the same area. Until recently, it was thought
that this particular susceptibility of women
to malaria during pregnancy was due to preg-
nancy-related immune suppression and hor-
monal alterations. However, it has been re-
cently shown that the placenta provides an
ideal environment for the development of a
subpopulation of malaria parasites that ad-
here to receptors in the placental syncy-
tiotrophoblast. In most cases, the parasites
remain on the maternal side of the placenta,
but this maternal-fetal syndrome, known as
PAM, has adverse effects on both mother
and unborn child, causing maternal anemia
and low-birth weight (LBW) babies (9). PAM
is thought to be responsible for 62,000 to
363,000 infant deaths in sub-Saharan Africa
annually (10). Unfortunately, these figures
are probably underestimates since peripher-
al parasitemia is not always observed and
the symptoms are not well characterized in
some cases.
In PAM, parasite adhesion to CSA, HA
and other placental receptors may trigger an
inflammatory process involving cytokine-
secreting mononuclear cells. The inflamma-
tory component, which may appear after
parasite accumulation in the placenta, is as-
sociated with the immune-pathological con-
sequences of PAM, such as cytotrophoblast
proliferation and cytotrophoblast membrane
thickening (10). This inflammatory process,
characterized by massive cell deposition, is
thought to alter local blood flow, disrupting
metabolic pathways and hindering IgG trans-
fer across the placenta and the exchange of
nutrients between mother and fetus, result-
ing in placental lesions and LBW (10,11).
However, the clinical outcomes of PAM,
such as fetal growth restriction and preterm
delivery, the strict association with LBW at
term and placental parasitemia, have been
observed in primigravidae (9). It is also
known that infants born to infected Cam-
eroonian mothers are significantly more sus-
ceptible to plasmodial infections, especially
in the first two years of life (11). A recent
epidemiological analysis in Tanzania, in-
cluding twice as many infants as the Cam-
eroon study (11), also showed that children
born to women with placental malaria pre-
sented parasitemia earlier in life than those
born to non-infected peers (12). Surpris-
ingly, this study also showed that parity
played a role, as the offspring of primi-
gravidae had a significantly lower risk of
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parasitemia than infants born to multi-
gravidae (12). The precise reasons for this
remain unclear, but the marked change in
cytokine profile and the timing of cytokine
production in primigravidae may be involved
(12).
Most studies of maternal malaria have
been carried out in P. falciparum-infected
women. However, pregnant women are sus-
ceptible to all four human malaria parasites,
including P. vivax, the most prevalent para-
site in Brazil and elsewhere outside sub-
Saharan Africa. A study in Thailand revealed
that primigravidae had a significantly higher
risk of P. vivax infection than multigravidae.
Moreover, P. vivax infection has also been
shown to be significantly associated with
maternal anemia and risk of LBW, although
these outcomes were more marked in multi-
gravidae (13). The deposition of malaria
pigment in the placenta has been observed in
P. vivax-infected women (14), and variant
antigens encoded by a specific P. vivax mul-
tigene family have been identified (15). How-
ever, hard data on P. vivax cytoadhesion to
the placental syncytiotrophoblast or endo-
thelial cells remain scarce.
In Brazil, where malaria transmission is
unstable, P. falciparum and P. vivax infec-
tions account for 15.1 and 84.4% of cases
among non-pregnant women (16). However,
the corresponding proportions for pregnant
women are 29.7% for falciparum and 67.7%
for vivax malaria (16). This corresponds to a
significant, 2.5 times increase in the fre-
quency of P. falciparum infection for the
195 cases of malaria in pregnant women
analyzed (16). The precise reason for this
shift in prevalence is unclear and further
studies with a larger number of patients are
required.
Ligands and receptors involved in
PAM
The DBL-γ3 domain of PfEMP-1, en-
coded by the var1CSA gene, was initially
thought to be the ligand responsible for para-
site cytoadhesion in PAM (17). However,
several recent studies have suggested that
the protein encoded by the var2CSA gene
may be the principal ligand involved in pla-
cental cytoadhesion. Unlike var1CSA, var2CSA
is up-regulated in placental parasites after
selection for adhesion to the CSA receptor in
vitro (18-20); indeed it is the only gene
shown to be transcriptionally up-regulated
following such selection. var2CSA knockout
parasites are unable to recover their initial
CSA binding, even after repeated exposure
to CSA (21,22). The PfEMP-1 encoded by
the var2CSA gene has been shown to have a
structure different from that of other var
genes, in that it lacks the CIDR, DBL-γ and
N-terminal DBL-α domains (Figure 2B).
The PfEMP-1 encoded by the 3D7 var2CSA
gene (3D7gDNA-PFL0030cvar) has six
DBL motifs: DBL4-ε, DBL5-ε and DBL6-ε,
and a further three motifs that do not fit into
the current classification: DBL1-X, DBL2-
X and DBL3-X. The DBL2-X and DBL6-ε
domains are able to bind CSA (Figure 2B)
(18).
A recent mass spectrometry-based prote-
omics study identified novel parasite anti-
gens, which might be expressed on the IE
surface, exclusively in CSA-binding or pla-
cental parasites, but did not evaluate the
binding of these antigens to host receptors
(23).
There is evidence that CSA is not the
only placental receptor and that a subpopu-
lation of parasites collected from infected
placentas may also bind to HA and to non-
immune IgG via their F(ab’) moieties. How-
ever, recent cytoadhesion assays using pla-
cental parasites collected from 60 pregnant
Tanzanian women with malaria showed that
almost all placental parasites capable of bind-
ing to at least one host receptor were also
able to adhere to immobilized CSA, and that
only three of 46 of these parasites adhered to
immobilized HA. In binding inhibition as-
says using soluble CSA as a competitor,
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adhesion to placental sections was signifi-
cantly abolished in all placental parasites
tested. In contrast, soluble HA, non-immune
IgG and protein A failed to inhibit parasite
binding to placental cryosections. These find-
ings strongly suggest that CSA is the major
placental receptor, and support the develop-
ment of vaccines targeting parasite ligands
to CSA (24).
The CSA or chondroitin 4-sulfate (C4S)
receptor is a glycosaminoglycan present in
the extracellular matrix, and was first identi-
fied as a receptor for parasite binding to
Saimiri monkey endothelial brain cells and
to Chinese hamster ovary cells (25,26). Gysin
et al. (27) showed that thrombomodulin with
a CSA chain was the dominant proteoglycan
involved in the sequestration of CSA-bind-
ing parasites in the placenta and that a CSA
chain at least 9 kDa in size was required to
sustain the adhesion of CSA-binding para-
sites (28). Achur et al. (29) subsequently
purified and identified several types of chon-
droitin sulfate proteoglycan (CSPG) from
the human placenta, showing that these natu-
ral CSPGs present in the intervillous space
contained unusually low levels of sulfate
and served as receptors for PAM parasite
adhesion. The same group went on to define
the structures required for parasite cyto-
adhesion as C4S dodecasaccharides, and
showed that these placental CSPGs have a
unique distribution of sulfate groups through-
out the second and third semesters of preg-
nancy (30-32). It was recently shown that
the ability of antiadhesive molecules to in-
hibit C4S-specific binding also depends on
the sulfation partner of these CSPGs (33).
Does the antibody-mediated
immune response play a role in
PAM?
Despite pregnancy-related immunosup-
pression, pregnant women with malaria de-
velop antibodies that inhibit the binding of
IE to CSA, and these antibodies are associ-
ated with protection against placental infec-
tion. Primigravidae have a much higher sus-
ceptibility to maternal malaria than multi-
gravidae, because the antibodies acquired
after multiple pregnancies are associated with
a reduction in the number of IE in the pla-
centa (34). In addition, higher levels of these
CSA adhesion-blocking antibodies are cor-
related with less pronounced maternal ane-
mia and with higher birth weight for babies
born at term (35,36).
For var2CSA parasites, a recent study
showed that rabbit antibodies raised against
two VAR2CSA recombinant proteins, cor-
responding to the DBL1-X and DBL5-ε do-
mains, recognize only the surface proteins
of PAM parasites (20). Plasma samples from
Ghanaian individuals recognized these re-
combinant proteins in a sex- and parity-
dependent manner in ELISA tests; this was
particularly true for the recombinant protein
based on the DBL5-ε domain (20). High
plasma levels of anti-VAR2CSA antibodies
in women were also found to be correlated
with a lower risk of LBW (20). Finally,
monoclonal antibodies (mAbs) that recog-
nize VAR2CSA DBL domains inhibit, to
various extents, the adhesion of a placental
isolate to placental cryosections under flow
conditions. Moreover, sera from mice im-
munized with native VAR2CSA domain
complexes with specific mAbs strongly in-
hibit PAM parasite cytoadhesion to CSA on
the surface of endothelial cells (37).
These observations suggest that one prob-
able mechanism controlling placental para-
sitemia and attenuating clinical outcome may
be based on adhesion-blocking antibodies
against CSA-binding domains. However, as
primigravidae and multigravidae present sig-
nificant levels of adhesion-blocking anti-
bodies at term, the timing of acquisition of
these antibodies may be important in im-
mune protection. O’Neil-Dunne et al. (38)
studied 198 pregnant Cameroonian women
and showed that multigravidae began mount-
ing an antibody-based immune response af-
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ter just 12 weeks of gestation, whereas primi-
gravidae took eight weeks longer to develop
such adhesion-blocking antibodies. How-
ever, as cytophilic antibodies have been col-
lected from infected pregnant women (39), it
should be borne in mind that other antibody-
dependent mechanisms, such as phagocyto-
sis and complement activation, may also
help to protect against PAM, in addition to
blocking adhesion. Consistent with the ex-
istence of additional antibody mechanisms,
Megnekou et al. (40) showed that IgG1 and
IgG3 were the most prevalent subclasses of
PAM antibodies in Cameroonian women,
and that larger amounts of these antibodies
were found in pregnant multiparous women.
Is the cell-mediated immune
response involved in PAM
pathogenesis or protection?
The precise mechanism by which PAM
parasites evade the immune system and the
possible involvement of a cell-mediated im-
mune response in protection remains unre-
solved. However, it has been shown that
massive sequestration of the parasite in the
placenta leads to a switch in the cell-medi-
ated immune response, typically from TH2
to TH1, resulting in the clinical manifesta-
tion of PAM, characterized by an increase in
the level of pro-inflammatory cytokine pro-
duction (10). Several studies have shown
that high levels of IFN-γ and TNF-α, mainly
secreted by placental macrophages, are as-
sociated with poor clinical outcome in pa-
tients with PAM and with the concentration
of hemozoin in the placenta (41). Placental
infection increases the levels of α- and ß-
chemokines, which, in turn, increase im-
mune cell recruitment to the placenta (10,42).
In contrast, IFN-γ levels have been re-
ported to be higher following in vitro stimu-
lation of blood mononuclear cells from mul-
tigravidae than following the stimulation of
such cells from women in their first or sec-
ond pregnancy. The cells collected from
women in their second pregnancy secreted
high levels of IL-4 and IL-10 (43). Multi-
gravidae have been shown to present higher
levels of lymphocyte proliferation and natu-
ral killer cell cytotoxic activity in response
to CSA-binding parasites than primigravidae
women (10). These observations suggest that
IFN-γ is involved in immunity to PAM.
Further evidence for the protective role of
IFN-γ is provided by the higher susceptibil-
ity to PAM of women with both malaria and
HIV infection (10). Indeed, it has been re-
cently shown that neonates born to mothers
with active placental infection have lower
levels of PAM-parasite antigen-specific IFN-
γ T cells and higher levels of IL-10 CD4 T
cells than do pregnant infected women treated
for malaria (44). However, TGF-ß, an anti-
inflammatory cytokine, is produced in larger
amounts in multigravidae than in primi-
gravidae, suggesting a possible role in con-
trolling the manifestation of PAM clinical
symptoms.
A recent study in monkeys showed that
infection with P. coatneyi did not result in
higher levels of CD4 and CD8 T lympho-
cytes than observed in infected non-preg-
nant monkeys. Indeed, the pregnant infected
monkeys had lower levels of monocytes and
macrophages in peripheral blood than did
the non-pregnant infected monkeys (45).
Conversely, high levels of mononuclear cell
accumulation have been associated with poor
PAM outcomes (46). It should be noted that,
in these studies, cells were counted in pe-
ripheral blood, so we cannot exclude the
possibility that this modulation may alter the
levels of these cells in placental compart-
ments. In PAM, T cells collected from pe-
ripheral blood proliferate more efficiently
than those collected from the intervillous
blood, whereas intervillous and peripheral
monocytes are equally able to present anti-
gens (47).
These observations suggest a dual effect
on cytokine production in PAM and that a
fine balance in the timing and levels of pro-
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and anti-inflammatory cytokines dictates
whether an individual will manage to con-
trol PAM or whether the clinical symptoms
associated with the disease will develop.
This dual effect may depend on regulation of
the macrophage migration inhibitory factor,
a specific cytokine that counter-regulates
the immunosuppressive effects of pregnancy.
Placental infection was recently shown to
increase macrophage migration inhibitory
factor production in the presence of cytotro-
phoblast-adherent IE (48).
Is an anti-PAM vaccine feasible?
The first evidence that it might be pos-
sible to develop an anti-PAM vaccine was
provided by the study of Fried and Duffy
(9,35) and Staalsoe et al. (34,36) showing
that multiparous women were less suscep-
tible to PAM than women in their first preg-
nancy, that infected women developed high
levels of adhesion-blocking antibodies
against PAM parasites after several preg-
nancies (9,34) and that these antibodies were
associated with attenuation of the clinical
outcome of PAM. Antibodies against var2CSA
parasites have also been shown to cross-
react with genetically different P. falcipa-
rum strains (49). Cross-reactivity between
the DBL-γ3CSA domain and var2CSA-encoded
antigens has been observed (50). Further-
more, mAbs raised against var2CSA parasite
surface antigens have also proved to be pan-
reactive with CSA-binding parasites from
different geographical origins (37). More-
over, molecular analysis of the var1CSA DBL-
γ3 minimal binding domain revealed 37%
sequence identity to the var2CSA DBL3-X
domain (51). These somewhat surprising pan-
reactivity results are probably related to con-
formational similarities.
In light of the antibody-mediated im-
mune response in PAM, an efficient vaccine
would probably elicit large amounts of ad-
hesion-blocking antibodies, mainly against
conserved binding motifs. However, as the
cell-mediated immune response also seems
to be involved in immune protection against
PAM, immunization regimes and adjuvants
should aim to induce high levels of IFN-γ-
secreting T cells. Immunization regimens
based on naked DNA for priming and re-
combinant viral vectors or proteins for boost-
ing have been shown to elicit high levels of
CD4- and CD8-producing T cells able to
induce immune protection against several
viral and protozoan diseases (52). Finally,
anti-PAM vaccines may contain other para-
site antigens since sera collected from Cam-
eroonian women showed a significant corre-
lation between low or null levels of anti-
bodies against the carboxyl-terminal 19-kDa
segment of the P. falciparum merozoite sur-
face protein-1 and the risk of PAM (53).
Is it possible to model PAM?
Reliable in vitro adhesion models are
required for the evaluation of potential vac-
cine candidates and the antibody-mediated
immune response directed against them. Most
of the existing in vitro models of IE seques-
tration were developed for studying IE adhe-
sion in parasites thought to be involved in
cerebral malaria. Many knob+ laboratory-
adapted P. falciparum strains adhere in vitro
to various cell types, including human um-
bilical vein endothelial cells, C32 amelanotic
melanoma cells, human dermal microvascu-
lar endothelial cells, human brain capillary
endothelial cells, human monocytes and
platelets, and transfected COS cells (54).
However, in 1995, Gay et al. (55) described
the use of Saimiri microvascular brain endo-
thelial cell clones differing in terms of the
expression of several combined surface mol-
ecules such as CD36, ICAM-1, E-selectin,
and CSA, permitting for the first time the
selection by cytoadhesion of distinct mono-
morphic adhesion phenotypes.
Each model attempts to simulate the in-
teraction between IE and the cerebral endo-
thelial cells, but none can be considered
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ideal. The Saimiri cell model has some ad-
vantages in that it allows in vitro cytoadhesion
studies, the results of which can be con-
firmed or rejected using the homologous
Saimiri/P. falciparum monkey model (56).
This model is also considered to be more
relevant than non-primate cell models due to
the phylogenetic proximity to humans. The
use of organ-specific endothelial cells ap-
pears to be particularly useful for structure-
function studies in which the native confor-
mation of a receptor is critical. A placental
BeWo-derived cell line has been success-
fully used to select monomorphic CSA-bind-
ing parasites (57). Since placental CSPGs
have an unusual sulfation pattern, BeWo
cells provide an alternative to cells of non-
placental origin in CSA-binding studies.
In all the parasite-binding assays de-
scribed above, cytoadhesion was investi-
gated under static conditions, in which sus-
pensions of IE were allowed to settle on a
confluent monolayer of cultured cells. This
method is technically simple, making it pos-
sible to carry out a large number of assays
simultaneously. However, static assays do
not model the dynamic blood flow condi-
tions encountered by IE in vivo.
In 1995, Cooke and Coppel (54) devel-
oped an in vitro assay for visualizing and
quantifying the adhesion of IE to endothelial
cells or to immobilized adhesion receptors
under flow conditions. The flow assembly
used consisted of a parallel-plate flow cham-
ber or a glass microcapillary tube (microslide)
on which a monolayer of endothelial cells,
such as human umbilical vein endothelial
cells, C32 melanoma cells, or Saimiri micro-
vascular brain endothelial cell clones (58),
can be cultured, or a plastic slide coated with
purified proteins, such as CD36, ICAM-1 or
thrombospondin, by adsorption. Adhesion
under dynamic flow conditions can be quan-
tified by counting adherent IE directly under
the microscope.
Nevertheless, with the exception of this
flow adhesion model using endothelial cells
and immobilized proteins, very few models
have been developed for studying placental
malaria. One example is the Saimiri (squir-
rel monkey) microvascular endothelial cell
line Sc17, which expresses a thrombomodu-
lin bearing only a CSA chain and a CD44-
csa isoform. The presence of the chondroitin
sulfate of thrombomodulin, or a CD44
isoform, on endothelial cells mimics, to some
extent, the presence of CSA on the surface of
the syncytiotrophoblast, thereby providing a
clear advantage over previous cell models or
commercial CSA preparations from various
non-placental sources (59). Conversely, one
major disadvantage of the use of cell lines as
models for CSA binding is the presence of
unidentified or unknown adhesion receptors
in addition to CSA on the surface of endo-
thelial cells. Another disadvantage of these
assays is that CSA preparations from vari-
ous sources, used by different laboratories,
can generate conflicting results. Thus, the
conformational modification of CSA by add-
ing dipalmitoyl-diphosphatidylethanolamine
may bias results, especially when this sys-
tem is used to select CSA-binding IE by
panning. The addition of charged groups
seems to be problematic for the specific
selection of CSA-binding IE from labora-
tory strains and field isolates (28). Further-
more, cytoadhesion inhibition assays with
Saimiri brain endothelial or Chinese ham-
ster ovary cells cannot distinguish between
subpopulations of CSA-binding parasites in
field samples.
However, most of these problems can be
solved by using normal and at-term human
placental cryosections (60), as IE bind al-
most exclusively to syncytiotrophoblast and
in the intervillous space containing proteo-
glycans with low levels of sulfation (61).
The use of human placental tissue makes it
much easier to count IE under flow than
under static conditions, in which parasites
also bind to CSA and to other receptors
within the villi. A comparison of inhibition
assays carried out under flow and static con-
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ditions revealed significant differences in
the presence of soluble CSA, or inhibitor
mAbs in serum samples from primi- and
multigravidae (61). Static parasite adhesion
assays are subject to considerable inter-ex-
perimental variation, due primarily to differ-
ences in washing procedures.
The use of placental cryosections made it
possible, for the first time, to measure the
shear-stress resistance of CSA-binding IE.
Distinct subpopulations within the CSA-
binding phenotype were identified by in-
creasing the flow rate gradually from 0.2 to
3.2 Pascal (Pa). For example, at 0.6 Pa,
which exceeds the normal shear stress in the
placenta (0.05 Pa), 70% of IE remained ad-
herent for the laboratory strain FCR3CSA,
and 25% of IE resisted a shear stress >3.2 Pa
(60).
These results strongly suggest that the
initial FCR3CSA strain was composed of a
mixture of strong (≥3.2 Pa) and weak (≤0.8
Pa) CSA-binding parasites, confirming the
existence of distinct adhesion subpopula-
tions among the CSA phenotypes of various
strains (58; Nogueira PA, Costa FT and Gysin
J, unpublished data), and supporting the hy-
pothesis that only some subpopulations of
CSA-binding IE have the potential for se-
questration in the microvasculature (58). This
hypothesis is based on the notion that IE in
the placenta are not normally exposed to
shear stresses exceeding 0.05 Pa, whereas
shear stresses in the postcapillary venules
vary from 0.1 to 1 Pa (58).
Conclusions
There is now considerable evidence that
PAM is a particularly severe form of ma-
laria, and that primigravidae and their off-
spring have a higher risk of developing PAM
than do multigravidae and their children.
These observations, and others, provide an
impetus for the development of an anti-PAM
vaccine. However, several issues concern-
ing the expression of antigens by PAM para-
sites and the precise immunological mechan-
isms involved in protection remain unre-
solved in the context of PAM. First, does the
unique set of hormones and cytokines in-
duced during gestation play a role in antigen
or placental host receptor expression? Sec-
ond, why is CSA the major PAM receptor,
given that this glycosaminoglycan is found
in various organs other than the placenta?
Third, how many antigenically different
PAM parasites exist, and what are their rela-
tive prevalences in infected pregnant women?
Fourth, what is the evolutionary importance
of this pan-reactivity and the presence of
multiple CSA-binding domains? Can these
domains be ordered into a hierarchy? Fi-
nally, as some of the poor placental out-
comes observed in falciparum malaria are
also observed in vivax malaria, is IE
cytoadhesion in the placenta an exclusive
feature of P. falciparum parasites? Or, like
the inhabitants of “Plato’s Cave”, are we
merely watching the “theater of shadows” of
real PAM parasite interactions and mechan-
isms reflected on the cave wall?
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